GRCE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GRCE is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a recent FDA-related setback, no fresh news catalyst, and the technical setup is mixed-to-weak despite being near support. Analyst targets were cut sharply, and there is no Intellectia buy signal today. The options market is extremely call-skewed, which suggests speculation rather than a clean long-term entry. My direct view: hold off for now.
Current pre-market price is 2.43, just above the pivot at 2.425, with resistance at 2.639 and support at 2.211. MACD histogram is positive at 0.0829 but contracting, which means bullish momentum is fading. RSI_6 at 46.485 is neutral, and moving averages are converging, indicating a lack of trend strength. The stock trend model also points to downside bias over multiple horizons, with a 60% chance of -0.96% next day, -2.94% next week, and -7.54% next month. Overall, the chart does not show a strong long-term entry setup right now.
["Only CMC-related FDA issues were cited, with no request for additional clinical data.", "Management plans a Type A meeting, which could clarify resubmission timing.", "Analyst firms still maintain Buy ratings despite cutting price targets.", "Options positioning is strongly call-skewed, indicating some market expectation of a rebound."]
["FDA CRL on GTx-104 citing CMC deficiencies and non-clinical concerns.", "Craig-Hallum cut target from $11 to $4.", "TD Cowen cut target from $12 to $8.", "Shares are unlikely to move higher until more visibility is provided.", "No news in the recent week.", "No recent insider buying/selling trend to support confidence.", "No recent congress trading data.", "Technical trend model suggests near-term downside."]
No usable financial snapshot was provided, so latest-quarter revenue/profit growth cannot be assessed. The missing financial data limits confidence in a long-term fundamental buy case, especially for a beginner investor.
Recent analyst trend is still Buy-rated, but price targets were cut materially after the FDA CRL. Craig-Hallum lowered its target to $4 from $11, and TD Cowen lowered its target to $8 from $12. The Wall Street pros view is mixed: they still believe the company can address the issues and resubmit, but they also expect a delay of roughly 12 months and see limited upside until more clarity arrives.
